atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
At-home abortions should be allowed for up to 12 weeks of pregnancy across the UK, according to academics, after a study found they were just as safe and effective as hospital care.
Read more here.
To explore possible treatments for various diseases, either animal models or human cell cultures are usually used first; however, animal models do not always mimic human diseases well, and cultures are far removed from tissue complexity. Advances in 3D printing,…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us